Skip to content

Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section

Analgesic Efficacy of Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section: A Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07170267
Enrollment
50
Registered
2025-09-12
Start date
2025-09-13
Completion date
2026-03-01
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transversalis Fascia Plane Block, Intrathecal Dexmedetomidine, Cesarean Section

Brief summary

This study aims to compare the analgesic efficacy of the transversalis fascia plane (TFP) block and intrathecal dexmedetomidine in patients undergoing cesarean section (CS).

Detailed description

Cesarean section (CS) is a commonly performed major surgical procedure that results in substantial postoperative pain and patient dissatisfaction. Spinal anesthesia is commonly used in CS surgery. However, it may be associated with several side effects, particularly hypotension. Dexmedetomidine is an α2 adrenergic receptor agonist that has an analgesic effect. Ultrasound-guided interfascial plane blocks are often used in multimodal analgesia regimens. Local anaesthetic injection into the transversalis fascia plane (TFP) anesthetizes the proximal branches of T12 and L1 which targeted in the plane between the transversus abdominis muscle and the transversalis fascia.

Interventions

Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.

Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 40 years. * American Society of Anesthesiology (ASA) physical status II. * Women undergoing cesarean section under spinal anesthesia.

Exclusion criteria

* Contraindication to spinal anesthesia. * Women with body mass index \>40 kg/m2. * Pregnancy-induced hypertension * Local infection at the site of injection. * Known cardiovascular disease * Coagulation abnormality. * History of chronic pain. * Abuse of drugs or alcohol. * History of allergies to any study medications. * Seizure disorders. * Any pregnancy complications requiring conversion to general anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
Degree of pain24 hours postoperativelyEach patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents no pain while 10 represents the worst pain imaginable). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 8, 12, 18 and 24 h postoperatively.

Secondary

MeasureTime frameDescription
Total morphine consumption24 hours postoperativelyRescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.
Time to the 1st rescue analgesia24 hours postoperativelyTime to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.
Mean arterial pressureTill the end of surgery (Up to 2 hours)Mean arterial pressure will be recorded preoperatively and every 30 minutes till the end of surgery.
Heart rateTill the end of surgery (Up to 2 hours)Heart rate will be recorded preoperatively and every 30 minutes till the end of surgery.
Incidence of adverse events24 hours postoperativelyIncidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.

Countries

Egypt

Contacts

Primary ContactMohammed S ElSharkawy, MD
mselsharkawy@med.tanta.edu.eg00201148207870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026